An independent safety board has reviewed all the available data on the AstraZeneca/Oxford University vaccine. The assessment concluded that there was no evidence that the adverse event was due to the vaccine.
AstraZeneca working in conjunction with the University of Oxford had a single test subject who developed a significant medical issue.
Emergency Use Authorization for at least one of the vaccines, could be issued as early as late next month or early in November.
Many of us are beginning to get a sense that we have fallen into a COVID-19 rhythm. That is both good and bad.
Countries across Europe are trying to put a lid on the new cases by clamping down on the highest-risk indoor settings that spur infection.
As we approach the latter part of the summer, people should be asking the question: “What will this year’s flu season look like?” A bad flu season, as we had 2 years ago, combined with COVID-19 would significantly run the risk of overwhelming the health system.
Total new cases throughout the world increased throughout June and July, peaking towards the end of June at slightly over a quarter million new cases per day.
Currently, the World Health Organization estimates that 16% of people infected with COVID 19 are asymptomatic and are still capable of transmission. The data also shows that up to 40% of novel coronavirus transmission comes from these people who are asymptomatic.
News on vaccines continues to be very promising. Several of these vaccines are going into final stage trials known as stage III.
The biggest issue of the week continues to be the ongoing disparity in case counts between the United States and the rest of the developed world.